The results of this clinical trial show a clear trend for responders to have higher Pt-DNA adduct levels 24 h after microdose administration, which supports the feasibility of patient stratification by the diagnostic microdosing approach. 3.5.2.
← all excerpts
Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science.
1
—
—